Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093740 | 1.00 | EPHX1 (0.32) | EPHX1GABRR1 | |
| SCHEMBL6021282 | 1.00 | EPHX1 (0.32) | EPHX1GABRR1 | |
| SCHEMBL491235 | 0.79 | — | — | |
| SCHEMBL5451266 | 0.78 | HCAR2 (0.37) | — | |
| SCHEMBL14152238 | 0.78 | CHRNB2 (0.41) | — | |
| SCHEMBL7946317 | 0.78 | CHRNB2 (0.39) | — | |
| SCHEMBL14889661 | 0.78 | CHRNB2 (0.39) | — | |
| SCHEMBL6053329 | 0.78 | CHRNB2 (0.41) | — | |
| SCHEMBL14655205 | 0.78 | CHRNB2 (0.41) | — | |
| SCHEMBL1246863 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072886-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | claimed |
| EP-2928867-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | claimed |
| EP-2771327-B1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | claimed |
| EP-2718266-B9 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-3072886-A1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | claimed |
| US-9409866-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-9403808-B2 | Pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | claimed |
| EP-2718266-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | claimed |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (US) | 2016-05-19 | — | — | US | claimed |
| US-9321727-B2 | Pyridine derivatives as agonists of the CB2 receptor | HOFFMANN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | claimed |
| WO-2014086805-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | claimed |
| EP-2718266-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | claimed |
| WO-2013060751-A1 | NOVEL PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-02 | — | — | WO | claimed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | claimed |
| WO-2012168350-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | claimed |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | claimed |
| EP-2076499-B1 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | claimed |
| US-7691863-B2 | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators | HOFFMAN-LA ROCHE INC. (US) | 2010-04-06 | — | — | US | claimed |
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | claimed |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | EPHX1 2613/4885GABRR1 1324/4885 |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | CNR2, CNR1, P2RY2 | EPHX1 1946/4885GABRR1 455/4885 |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | EPHX1 853/4885GABRR1 1674/4885 |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | CNR2, CNR1, GPR174 | EPHX1 1707/4885GABRR1 677/4885 |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | EPHX1 853/4885GABRR1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.